Carregant...
Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions
Since the approval of anti-CTLA4 therapy (ipilimumab) for late-stage melanoma in 2011, the development of anticancer immunotherapy agents has thrived. The success of many immune-checkpoint inhibitors has drastically changed the landscape of cancer treatment. For some types of cancer, monotherapy for...
Guardat en:
| Publicat a: | Front Pharmacol |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5844965/ https://ncbi.nlm.nih.gov/pubmed/29556198 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2018.00185 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|